Objectives. To evaluate the potential prognostic utility of pretreatment systemic immune-inflammation index (SII) in newly diagnosed glioblastoma multiforme (GBM) patients who underwent postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide. Methods. The retrospective data of GBM patients who underwent postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide were analyzed. For each patient, SII was calculated using the platelet, neutrophil, and lymphocyte measures obtained on the first day of treatment: . The receiver operating characteristic (ROC) curve analysis was utilized for the evaluation of optimal cut-off values for SII those linked with the outcomes. Primary and secondary endpoints constituted the overall (OS) and progression-free survival (PFS) per conveyance SII group. Results. A total of 167 patients were included. The ROC curve analysis identified the optimum SII cut-off at a rounded 565 value that significantly interacted with the PFS and OS and stratified patients into two groups: low-SII (; ) and high-SII (; ), respectively. Comparative survival analyses exhibited that the high-SII cohort had significantly shorter median PFS (6.0 versus 16.6 months; ) and OS (11.1 versus 22.9 months; ) than the low-SII cohort. The relationship between the high-SII and poorer PFS () and OS () further retained its independent significance in multivariate analysis, as well. Conclusions. The outcomes displayed here qualified the pretreatment SII as a novel independent prognostic index for predicting survival outcomes of newly diagnosed GBM patients undergoing postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide.

中文翻译：

---

多形性胶质母细胞瘤患者接受神经外科术后放疗加同时和辅助替莫唑胺治疗前全身免疫炎症指数的预后价值。

目标。评估预处理全身免疫炎症指数 (SII) 在新诊断的多形性胶质母细胞瘤 (GBM) 患者中的潜在预后效用，这些患者接受了神经外科手术后放疗和同时加辅助替莫唑胺。方法。对接受神经外科手术后放疗和同期加辅助替莫唑胺治疗的GBM患者的回顾性资料进行分析。对于每位患者，使用治疗第一天获得的血小板、中性粒细胞和淋巴细胞测量值计算 SII：. 受试者工作特征 (ROC) 曲线分析用于评估与结果相关的 SII 的最佳截止值。主要和次要终点构成每个运输 SII 组的总体 (OS) 和无进展生存期 (PFS)。结果。共纳入 167 名患者。ROC 曲线分析确定了最佳 SII 截断值，取整为 565，与 PFS 和 OS 显着相互作用，并将患者分为两组：低 SII（; )和高 SII (; )，分别。比较生存分析表明，高 SII 队列的中位 PFS 显着缩短（6.0 对 16.6 个月；)和 OS（11.1 个月对 22.9 个月；)比低 SII 队列。高 SII 与较差 PFS 之间的关系（)和操作系统 ()在多变量分析中也进一步保留了其独立意义。结论。这里显示的结果使治疗前 SII 成为一种新的独立预后指标，用于预测新诊断的 GBM 患者接受神经手术后放疗和同时加辅助替莫唑胺的生存结果。